文献速递肝病

健康体检队列中代谢功能障碍相关脂肪性肝病合并中度饮酒患者的无创检查诊断效能

Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort.
PubMed 文献 · J Hepatol · 2024-06-13

本横断面研究纳入7918名同时接受磁共振弹性成像和超声检查的健康体检者,分为代谢功能障碍相关脂肪性肝病(MASLD)组与MASLD合并中度饮酒(MetALD)组,评估FIB-4和NAFLD纤维化评分对进展期肝纤维化(MRE≥3.6 kPa)的诊断效能,发现两组诊断效能相似,FIB-4在MetALD初始筛查中表现良好。

要点

  • 健康体检队列中MetALD患病率为5.8%,其中1.5%存在进展期肝纤维化。
  • FIB-4诊断MRE≥3.6 kPa的曲线下面积在MetALD组为0.85,MASLD组为0.80。
  • FIB-4对MetALD的敏感性71.4%、特异性77.3%、阳性预测值4.6%、阴性预测值99.4%。

核心结论

  • FIB-4在MetALD进展期肝纤维化初始筛查中表现良好,具有合理的敏感性和阴性预测值。

研究设计与样本

  • 横断面研究,回顾性分析7918名同时接受磁共振弹性成像和超声检查的健康体检者数据。
  • 参与者分为MASLD组和MetALD组,评估FIB-4和NAFLD纤维化评分(NFS)的诊断效能。
  • 进展期肝纤维化(F3)定义为磁共振弹性成像≥3.6 kPa。

主要发现

  • 健康体检队列中MetALD患病率为5.8%,其中1.5%存在进展期肝纤维化。
  • MetALD与MASLD具有相似的代谢特征和肝纤维化负担。
  • FIB-4诊断MRE≥3.6 kPa的曲线下面积在MetALD组为0.85,MASLD组为0.80(原文未报告组间差异的统计学检验)。
  • FIB-4对MetALD的敏感性71.4%、特异性77.3%、阳性预测值4.6%、阴性预测值99.4%,与MASLD组所见密切接近。

关键数值与推荐

  • 进展期肝纤维化(F3)定义为磁共振弹性成像≥3.6 kPa。
  • MetALD患病率为5.8%,其中1.5%存在进展期肝纤维化。
  • FIB-4诊断MRE≥3.6 kPa的曲线下面积:MetALD组0.85 vs MASLD组0.80。
  • FIB-4对MetALD的敏感性71.4%、特异性77.3%、阳性预测值4.6%、阴性预测值99.4%。

临床怎么用

  • 作者认为FIB-4是识别MetALD人群进展期肝纤维化的有价值筛查工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Non-invasive tests (NITs) for liver fibrosis have been recognized for their clinical utility in metabolic dysfunction-associated steatotic liver disease (MASLD). However, their diagnostic efficacy in detecting liver fibrosis is notably reduced in patients with alcohol-related liver disease. Therefore, ascertaining the reliability of NITs in patients with MASLD with moderate alcohol intake (MetALD) is essential. METHODS: In this cross-sectional study, we reviewed data from 7,918 health check-up participants who underwent both magnetic resonance elastography (MRE) and ultrasound for the diagnosis of hepatic steatosis. The participants were categorized into MASLD and MetALD groups, and the performance of fibrosis-4 index (FIB-4) and NAFLD fibrosis score (NFS) were assessed. Advanced hepatic fibrosis (F3) was defined as MRE ≥3.6 kPa. RESULTS: The prevalence of MetALD was 5.8% in this health check-up cohort, and 1.5% of these patients exhibited advanced hepatic fibrosis. Both MetALD and MASLD displayed similar metabolic profiles and hepatic fibrosis burdens. The diagnostic performance of FIB-4 and NFS for MRE ≥3.6 kPa showed no noticeable differences in the area under the receiver-operating characteristic values between the two groups (0.85 vs. 0.80 in FIB-4). Moreover, the sensitivity (71.4%), specificity (77.3%), and both positive (4.6%) and negative (99.4%) predictive values of NITs for MetALD closely mirrored those observed for MASLD. CONCLUSION: FIB-4 performed well for the initial screening of advanced hepatic fibrosis in MetALD, demonstrating reasonable sensitivity and negative predictive values. IMPACT AND IMPLICATIONS: In this cross-sectional study, data from 7,918 participants who underwent MRE were analyzed to assess the performance of fibrosis-4 (FIB-4) and non-alcoholic fatty liver disease fibrosis scores in metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with moderate alcohol intake (MetALD). We found that FIB-4 had high diagnostic accuracy in the newly identified MetALD group, similar to that in the MASLD population. These results highlight the potential of FIB-4 as a reliable screening tool for MetALD, even when specific subgroups are considered. Therefore, FIB-4 is a valuable screening tool for identifying advanced fibrosis in the MetALD population.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Oh JH, Ahn SB, Cho S, et al. Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort. J Hepatol. 2024. PMID: 38879175. doi:10.1016/j.jhep.2024.05.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。